Literature DB >> 25285690

Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer.

Francesco Stipa1, Marcello Picchio, Antonio Burza, Emanuele Soricelli, Carlo Eugenio Vitelli.   

Abstract

BACKGROUND: Local excision, as an alternative to radical resection for patients with pathological complete response (ypT0) after preoperative chemoradiation, is under investigation.
OBJECTIVE: The aim of the present study was to evaluate the long-term clinical outcome of a selected group of patients with ypT0 rectal cancer who underwent local excision with transanal endoscopic microsurgery as a definitive treatment. PATIENTS: Between 1993 and 2013, 43 patients with rectal adenocarcinoma underwent complete full-thickness local excision with a transanal endoscopic microsurgery procedure after a regimen of chemoradiation. In all patients, rectal wall penetration was preoperatively assessed by endorectal ultrasound and/or magnetic resonance. Chemoradiation and transanal endoscopic microsurgery were indicated in patients refusing radical procedures or patients unfit for major abdominal procedures. MAIN OUTCOME MEASURES: Patient characteristics, operative record, pathology report, and tumor recurrence were analyzed at a median follow-up of 81 months. The potential prognostic factors for recurrence, screened in univariate analysis, were analyzed by multivariate analysis by using the Cox regression model.
RESULTS: Thirteen patients (30.2%), without residual tumor in the surgical specimen (ypT0), were treated with transanal endoscopic microsurgery only. In this ypT0 group, 2 patients (15.4%) had postoperative complications: 1 bleeding and 1 suture dehiscence. Postoperative mortality was nil. No local and distal recurrences were observed, and no tumor-related mortality occurred. In 30 patients (69.8%), partial tumor chemoradiation response or the absence of tumor chemoradiation response was observed. In this group, recurrence occurred in 17 patients (56.7%). LIMITATIONS: The study was limited by its retrospective nature, different protocols of chemoradiation and preoperative staging over time, and the small sample size.
CONCLUSIONS: Local excision with transanal endoscopic microsurgery can be considered a definitive therapeutic option in patients with rectal cancer treated with preoperative chemoradiation, when no residual tumor is found in the specimen. In this selected group, local excision offers excellent results in terms of survival and recurrence rates. In the presence of residual tumor, transanal endoscopic microsurgery should be considered as a large excisional biopsy (see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A157).

Entities:  

Mesh:

Year:  2014        PMID: 25285690     DOI: 10.1097/DCR.0000000000000221

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  11 in total

1.  Does total regression of primary rectal cancer after preoperative chemoradiotherapy represent "no tumor" status?

Authors:  Seong-A Jeong; In Ja Park; Seung Mo Hong; Jun Woo Bong; Hye Yoon Choi; Ji Hyun Seo; Hyong Eun Kim; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  Ann Surg Treat Res       Date:  2018-01-30       Impact factor: 1.859

2.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

Review 3.  Local excision by transanal endoscopic surgery.

Authors:  Luis J García-Flórez; Jorge L Otero-Díez
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

4.  Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation.

Authors:  Juefeng Wan; Kaitai Liu; Ji Zhu; Guichao Li; Zhen Zhang
Journal:  Oncotarget       Date:  2015-05-10

5.  Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer.

Authors:  Young Seob Shin; Yong Sik Yoon; Seok-Byung Lim; Chang Sik Yu; Tae Won Kim; Heung Moon Chang; Jin-Hong Park; Seung Do Ahn; Sang-Wook Lee; Eun Kyung Choi; Jin Cheon Kim; Jong Hoon Kim
Journal:  Radiat Oncol J       Date:  2016-09-28

Review 6.  Current debate in the oncologic management of rectal cancer.

Authors:  Trish Millard; Paul R Kunk; Erika Ramsdale; Osama E Rahma
Journal:  World J Gastrointest Oncol       Date:  2016-10-15

Review 7.  Controversial issues in radiotherapy for rectal cancer: a systematic review.

Authors:  Jong Hoon Kim
Journal:  Radiat Oncol J       Date:  2017-12-29

8.  Long-term outcomes of transanal endoscopic microsurgery for clinical complete response after neoadjuvant treatment in T2-3 rectal cancer.

Authors:  Javier Ernesto Barreras González; Haslen Cáceres Lavernia; Jorge Gerardo Pereira Fraga; Solvey Quesada Lemus
Journal:  Surg Endosc       Date:  2021-07-06       Impact factor: 4.584

9.  Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study.

Authors:  A J M Rombouts; N Hugen; M A G Elferink; I D Nagtegaal; J H W de Wilt
Journal:  Ann Surg Oncol       Date:  2016-06-01       Impact factor: 5.344

10.  Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jing Yu; Ning Li; Xin Wang; Hua Ren; Weihu Wang; Shulian Wang; Yongwen Song; Yueping Liu; Yexiong Li; Xuantong Zhou; Aiping Luo; Zhihua Liu; Jing Jin
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.